Investigating how Type 3 Innate Lymphoid Cells affect melanoma tumors
Official title: The frequency and function of Type 3 Innate Lymphoid Cells regulates the melanoma tumor microenvironment
Funded at Duke University · NIH-10993053 · Data updated 2026-11-12
This study is looking at how certain immune cells called ILC3s behave in melanoma tumors to see if they affect how well treatments work, especially for patients who haven't had success with current therapies, with the hope of finding better ways to help them.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $77,284 |
| NIH project number | 1F32CA294631-01 |
| Project ID | NIH-10993053 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults with advanced melanoma, especially those who have not responded to immune checkpoint inhibitor therapy.
✕Less likely to help
Patients with early-stage melanoma or those who have not undergone immune checkpoint inhibitor therapy may not benefit from this research.
What this research studies
This research explores the role of Type 3 Innate Lymphoid Cells (ILC3s) in the melanoma tumor microenvironment. It aims to understand how these cells influence immune responses and contribute to the effectiveness of immune checkpoint inhibitors in treating advanced melanoma. By examining the interactions between ILC3s and other immune cells, the study seeks to identify potential mechanisms that lead to treatment resistance in patients. The findings could help tailor more effective therapies for melanoma patients who currently do not respond to existing treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for melanoma patients, particularly those who do not respond to current therapies.
How similar studies have gone: Previous research has shown promising results in understanding the role of immune cells in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: O'connor, Margaret — Duke University
- Study coordinator: O'connor, Margaret
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.